Genmab As Stock Investor Sentiment

GMAB Stock  USD 20.65  0.18  0.88%   
About 50% of Genmab AS's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Genmab AS suggests that some traders are interested. The current market sentiment, together with Genmab AS's historical and current headlines, can help investors time the market. In addition, many technical investors use Genmab AS stock news signals to limit their universe of possible portfolio assets.

Panic Vs Confidence

50

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Genmab AS's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Genmab AS.

Genmab Historical Sentiment

Although Genmab AS's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Genmab, such as negative comments on social media and news outlets, may cause fear in the market and push Genmab AS's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Genmab.
  

Genmab AS Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Genmab AS can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Genmab AS Historical Investor Sentiment

Investor biases related to Genmab AS's public news can be used to forecast risks associated with an investment in Genmab. The trend in average sentiment can be used to explain how an investor holding Genmab can time the market purely based on public headlines and social activities around Genmab AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Genmab AS's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Genmab AS and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Genmab AS news discussions. The higher the estimate score, the more favorable the investor's outlook on Genmab AS.
over three months ago at businesswire.com         
TEPKINLY Receives Second European Commission Approval for the Treatment of Adults with RelapsedRefra...
businesswire News
over three months ago at news.google.com         
Short Interest in Genmab AS Increases By 33.3 percent - Defense World
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Genmab Announces Changes to its Executive Committee
Yahoo News
over three months ago at insidermonkey.com         
Genmab AS Q2 2024 Earnings Call Transcript
insidermonkey News
over three months ago at globenewswire.com         
Transactions with shares and linked securities in Genmab AS made by managerial employees and their c...
Macroaxis News: globenewswire.com
over three months ago at finance.yahoo.com         
Transactions with shares and linked securities in Genmab AS made by managerial employees and their c...
Yahoo News
over three months ago at investing.com         
Earnings call Genmab announces robust H1 2024 financials, drug approvals
Investing News at Macroaxis
over three months ago at investorplace.com         
GMAB Stock Earnings Genmab Misses EPS, Beats Revenue for Q2 2024
sbwire news
over three months ago at finance.yahoo.com         
Multispecific Antibodies Market Research, Drug Sales, Price Clinical Trials Insights 2023-2029 13 Ap...
Yahoo News
over three months ago at seekingalpha.com         
Genmab reports 1H results
seekingalpha News
over three months ago at finance.yahoo.com         
BioNTechs Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases RD Spe...
Yahoo News
over three months ago at seekingalpha.com         
Genmab stock slides 7 percent as BioNTech ends acasunlimab collaboration
seekingalpha News
over three months ago at finance.yahoo.com         
BioNTechs Loss Quadruples as COVID-19 Vaccine Demand Falls
Yahoo News
over three months ago at finance.yahoo.com         
Genmab Takes Full Control of Acasunlimab Development Program
Yahoo News
over three months ago at benzinga.com         
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
benzinga news
Far too much social signal, news, headlines, and media speculation about Genmab AS that are available to investors today. That information is available publicly through Genmab media outlets and privately through word of mouth or via Genmab internal channels. However, regardless of the origin, that massive amount of Genmab data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Genmab AS news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genmab AS relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genmab AS's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genmab AS alpha.

Genmab AS Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Is Genmab AS One of the Best Revenue Growth Stocks to Buy According to Analysts
09/30/2024
2
Genmab Announces Net Sales of DARZALEX for Third Quarter of 2024
10/15/2024
3
Genmab AS Leading Innovation in Antibody Therapeutics
10/17/2024
4
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology Annual Meeting
11/05/2024
5
Genmab Announces Financial Results for the First Nine Months of 2024
11/06/2024
6
Genmab AS Receives Consensus Rating of Moderate Buy from Brokerages
11/07/2024
7
Genmab AS Releases Quarterly Earnings Results, Misses Expectations By 0.03 EPS
11/08/2024
8
BMO Capital Markets Reiterates Outperform Rating for Genmab AS
11/12/2024
9
GENMAB ASS Shares Up 0.4 percent Still a Buy
11/19/2024
10
Genmab issues stock units and warrants to employees
11/21/2024

Complementary Tools for Genmab Stock analysis

When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins